FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366759859> ?p ?o ?g. }

• W4366759859 endingPage "1138" @default.
• W4366759859 startingPage "1129" @default.
• W4366759859 abstract "AbstractIbrutinib has dramatically changed the treatment landscape for chronic lymphocytic leukemia (CLL) since its availability in British Columbia (BC), Canada in 2014. We analyzed patterns of use and real-world survival outcomes in 370 patients who received ibrutinib for first-line (1 L, n = 35) and relapsed/refractory (R/R, n = 335) CLL between 2014–2018 in BC. Dose reductions and interruptions were frequent in 32% and 27%, respectively. With a median follow-up of 27.6 months, 35% of patients discontinued ibrutinib, primarily for adverse events (AEs) rather than progressive disease. Over the course of treatment, 87% of patients experienced at least one adverse event. The 2-year overall survival (OS) and event-free survival (EFS) were excellent at 83.9% and 76.1%, respectively, with medians not reached. However, patients who discontinued ibrutinib had a median OS of 32.5 months and median EFS of only 3.8 months from time of discontinuation, highlighting the need to minimize toxicity in the real-world.Keywords: Chronic lymphocytic leukemiaibrutinibBTK inhibitorpopulation-basedreal-world Author contributionsR.S.K, C.L.T. and A.S.G. conceived the research. R.S.K. and S.J.H. collected the data. R.S.K. and A.S.G. completed the data cleaning, analyzed the data, performed the statistical analysis, and drafted the original manuscript. All remaining authors assisted in the data collection and revision of the manuscript.Disclosure statementK.J.S. has received research funding from Roche, honoraria from Merck, BMS, Seattle Genetics, Gilead, AstraZeneca, Abbvie and serves on the Steering Committee for BeiGene. D.V. has received research funding from Roche and AstraZeneca and honoraria from BMS/Celgene, Janssen, Roche, AstraZeneca, Kite/Gilead and Abbvie. D.W.S. has received research funding from Roche/Genentech and Janssen, consultancy fees from AbbVie, AstraZeneca, Incyte, and Janssen and has patents and royalties with NIH and Nanostring. K.R. is an advisory board consultant for AstraZeneca, AbbVie and Janssen. L.H.S. has received research funding from Genentech Inc, F. Hoffmann-La Roche Ltd and Teva and honoraria from Amgen, AbbVie, Apobiologix, AstraZeneca, Genentech Inc, Acerta, Celgene, Janssen, Kite, Gilead, Karyopharm, Lundbeck, Merck, MorphoSys, F. Hoffmann-La Roche Ltd, Seattle Genetics, Teva, Takeda, Servier, Chugai, TG therapeutics and Verastem Oncology. C.L.T. has received research funding and honoraria from Janssen and AstraZeneca. A.S.G. has received research funding from Roche, AstraZeneca, AbbVie, and Janssen, and honoraria from Sandoz, AstraZeneca, AbbVie and Janssen. The remaining authors have no conflicts of interest to declare.Additional informationFundingR.S.K. was funded by the Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate Scholarship – Master’s (CGS-M) and a UBC Hematology Research Program Research Grant. We acknowledge the following companies for providing funding for the BC CLL Provincial Database: AstraZeneca Canada, Janssen Inc., Abbvie Inc., GlaxoSmithKline (Canada) Inc., Gilead Canada Sciences, Inc., Lundbeck Canada Inc., and Roche Ltd. (Canada)." @default.
• W4366759859 created "2023-04-24" @default.
• W4366759859 creator A5006888644 @default.
• W4366759859 creator A5017873196 @default.
• W4366759859 creator A5020565431 @default.
• W4366759859 creator A5021133318 @default.
• W4366759859 creator A5022658681 @default.
• W4366759859 creator A5026641386 @default.
• W4366759859 creator A5027561362 @default.
• W4366759859 creator A5045731423 @default.
• W4366759859 creator A5082635085 @default.
• W4366759859 creator A5086549204 @default.
• W4366759859 date "2023-04-22" @default.
• W4366759859 modified "2023-10-04" @default.
• W4366759859 title "Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada" @default.
• W4366759859 cites W1983395516 @default.
• W4366759859 cites W2023976667 @default.
• W4366759859 cites W2071549499 @default.
• W4366759859 cites W2108206643 @default.
• W4366759859 cites W2120319857 @default.
• W4366759859 cites W2140395974 @default.
• W4366759859 cites W2140606816 @default.
• W4366759859 cites W2144617723 @default.
• W4366759859 cites W2151177887 @default.
• W4366759859 cites W2589238872 @default.
• W4366759859 cites W2594686567 @default.
• W4366759859 cites W2609107614 @default.
• W4366759859 cites W2784507549 @default.
• W4366759859 cites W2787916641 @default.
• W4366759859 cites W2902034029 @default.
• W4366759859 cites W2902484351 @default.
• W4366759859 cites W2907375267 @default.
• W4366759859 cites W2911561350 @default.
• W4366759859 cites W2912712454 @default.
• W4366759859 cites W2922286357 @default.
• W4366759859 cites W2941780980 @default.
• W4366759859 cites W2945503799 @default.
• W4366759859 cites W2957723335 @default.
• W4366759859 cites W2964876593 @default.
• W4366759859 cites W2966190920 @default.
• W4366759859 cites W2976280418 @default.
• W4366759859 cites W2978550355 @default.
• W4366759859 cites W2980937306 @default.
• W4366759859 cites W3016001018 @default.
• W4366759859 cites W3031555133 @default.
• W4366759859 cites W3040369595 @default.
• W4366759859 cites W3045542125 @default.
• W4366759859 cites W3046303902 @default.
• W4366759859 cites W3049118620 @default.
• W4366759859 cites W3113192766 @default.
• W4366759859 cites W3128800233 @default.
• W4366759859 cites W3185756680 @default.
• W4366759859 cites W3203517382 @default.
• W4366759859 cites W3212072469 @default.
• W4366759859 cites W4296529230 @default.
• W4366759859 cites W4313575102 @default.
• W4366759859 doi "https://doi.org/10.1080/10428194.2023.2199340" @default.
• W4366759859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37086469" @default.
• W4366759859 hasPublicationYear "2023" @default.
• W4366759859 type Work @default.
• W4366759859 citedByCount "1" @default.
• W4366759859 countsByYear W43667598592023 @default.
• W4366759859 crossrefType "journal-article" @default.
• W4366759859 hasAuthorship W4366759859A5006888644 @default.
• W4366759859 hasAuthorship W4366759859A5017873196 @default.
• W4366759859 hasAuthorship W4366759859A5020565431 @default.
• W4366759859 hasAuthorship W4366759859A5021133318 @default.
• W4366759859 hasAuthorship W4366759859A5022658681 @default.
• W4366759859 hasAuthorship W4366759859A5026641386 @default.
• W4366759859 hasAuthorship W4366759859A5027561362 @default.
• W4366759859 hasAuthorship W4366759859A5045731423 @default.
• W4366759859 hasAuthorship W4366759859A5082635085 @default.
• W4366759859 hasAuthorship W4366759859A5086549204 @default.
• W4366759859 hasConcept C126322002 @default.
• W4366759859 hasConcept C143998085 @default.
• W4366759859 hasConcept C197934379 @default.
• W4366759859 hasConcept C2777938653 @default.
• W4366759859 hasConcept C2778461978 @default.
• W4366759859 hasConcept C2778715236 @default.
• W4366759859 hasConcept C2779878957 @default.
• W4366759859 hasConcept C2908647359 @default.
• W4366759859 hasConcept C71924100 @default.
• W4366759859 hasConcept C99454951 @default.
• W4366759859 hasConceptScore W4366759859C126322002 @default.
• W4366759859 hasConceptScore W4366759859C143998085 @default.
• W4366759859 hasConceptScore W4366759859C197934379 @default.
• W4366759859 hasConceptScore W4366759859C2777938653 @default.
• W4366759859 hasConceptScore W4366759859C2778461978 @default.
• W4366759859 hasConceptScore W4366759859C2778715236 @default.
• W4366759859 hasConceptScore W4366759859C2779878957 @default.
• W4366759859 hasConceptScore W4366759859C2908647359 @default.
• W4366759859 hasConceptScore W4366759859C71924100 @default.
• W4366759859 hasConceptScore W4366759859C99454951 @default.
• W4366759859 hasFunder F4320307773 @default.
• W4366759859 hasFunder F4320309117 @default.
• W4366759859 hasFunder F4320323180 @default.
• W4366759859 hasFunder F4320331229 @default.
• W4366759859 hasIssue "6" @default.

• next